Mereo Biopharma Group Plc (MREO) Securities Class Action Lawsuit Update [February 17, 2026]

Mereo BioPharma Securities Class Action Centers on Failed Phase 3 Setrusumab Trials

• Case Name: Dodge v. Mereo Biopharma Group Plc et al.
• Case No.: 1:26-cv-988
• Jurisdiction: U.S. District Court, Southern District of New York
• Filed on: February 4, 2026
• Class Period: June 5, 2023-December 26, 2025

Introduction

Mereo BioPharma Group plc is facing a federal securities class action after investors allege the company made misleading statements about the prospects for its lead drug candidate, setrusumab, in Phase 3 clinical trials. The lawsuit follows two sharp stock declines tied to disclosures that the company’s Phase 3 ORBIT and COSMIC studies failed to meet their primary endpoints.

Filed in the Southern District of New York, the complaint alleges that Mereo and senior executives repeatedly assured investors that improvements in bone mineral density would translate into fewer fractures for patients with osteogenesis imperfecta. Plaintiffs allege those assurances were misleading and that the truth emerged as the Phase 3 trial results were disclosed.

“Most MREO shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Mereo BioPharma Group plc is a London-based biopharmaceutical company focused on rare diseases. Its business model centers on acquiring and advancing drug candidates that have already undergone substantial development at larger pharmaceutical companies.

A cornerstone of that strategy was setrusumab, an anti-sclerostin antibody originally acquired from Novartis and later partnered with Ultragenyx Pharmaceutical Inc. Under the collaboration agreement described in the complaint, Ultragenyx received an exclusive license to develop and commercialize setrusumab outside Europe, while Mereo retained rights in Europe.

By 2023, setrusumab was a key clinical program for the company during the class period. The company positioned the drug as a potential first-in-class therapy for osteogenesis imperfecta, a genetic bone disorder marked by frequent fractures. The Phase 3 program was an important milestone for the drug’s development.

Promises Made vs. Reality

Throughout the class period, Mereo highlighted strong Phase 2 data showing significant increases in bone mineral density. Executives and investigators emphasized fracture-rate reductions observed in earlier studies and expressed confidence that these results would carry over into Phase 3.

Public statements stressed that increased bone density was a reliable proxy for reduced fracture risk. According to the complaint, defendants told investors that increases in bone mineral density observed in earlier studies were expected to translate into reductions in fracture rates in the Phase 3 trials.

Plaintiffs allege that these statements omitted a critical limitation: Phase 2 data lacked the control groups necessary to establish whether fracture reductions were attributable to the drug itself rather than standard of care or placebo effects. When Phase 3 data arrived, bone density improved—but fracture reduction did not reach statistical significance.

Timeline of Alleged Misconduct and Disclosures

The complaint outlines a steady cadence of optimistic updates from mid-2023 through late-2025. Press releases, earnings calls, and investor conferences reinforced confidence ahead of interim analyses.

On July 9, 2025, Mereo disclosed that the ORBIT study failed to achieve statistical significance at a key interim analysis. Shares fell roughly 42% the following day. Despite this setback, the company continued to emphasize confidence in final results. The decisive disclosure came on December 29, 2025, when Mereo announced that neither ORBIT nor COSMIC met their primary endpoints. The stock fell again, this time by more than 87% in a single session, erasing much of the company’s market value.

Investor Harm and Market Reaction

According to the complaint, investors who purchased Mereo ADS between June 5, 2023, and December 26, 2025, suffered substantial losses as the alleged misstatements were revealed.

The July 2025 disclosure triggered immediate analyst reassessments, with price targets cut amid uncertainty around regulatory prospects. The December 2025 announcement prompted sharper reactions. Multiple firms issued downgrades, pointing to the failure of the trials to demonstrate statistically significant fracture reduction.

Plaintiffs allege that these losses were directly tied to the revelation that prior statements about trial success were misleading.

Litigation and Procedural Posture

The action is brought on behalf of purchasers of Mereo ADS during the class period and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. Defendants include Mereo BioPharma Group plc, CEO Denise Scots-Knight, and Chief Scientific Officer John A. Lewicki.

The complaint alleges scienter based on defendants’ access to non-public clinical data and their continued reliance on Phase 2 results despite known limitations. It also alleges that repeated assurances after the failed interim analysis deepened investor losses.

The case remains pending in the U.S. District Court for the Southern District of New York.

Shareholder Sentiment

Investor sentiment toward Mereo BioPharma shifted sharply as the company’s Phase 3 trial disclosures unfolded. Earlier in the Class Period, discussions on retail investor platforms such as Stocktwits and Reddit reflected optimism around the company’s partnership with Ultragenyx and the potential of setrusumab as a treatment for osteogenesis imperfecta. Many investors pointed to earlier clinical data showing improvements in bone mineral density as a positive signal for the drug’s prospects. That optimism weakened after the July 2025 interim update showed the ORBIT trial failed to meet the statistical threshold required to stop early. Debate across investor forums intensified over whether bone mineral density improvements would translate into meaningful fracture reductions.

The reaction turned more negative after Mereo announced on December 29, 2025 that both the ORBIT and COSMIC Phase 3 trials failed to meet their fracture-reduction endpoints. While bone mineral density improved, the outcome prompted investors across retail forums and financial platforms to reassess the company’s valuation and the strength of its remaining pipeline.

Analyst Commentary

The professional analyst community, which had largely maintained "Buy" or "Outperform" ratings on Mereo, was forced into a sharp price-target cuts and lowered expectations.

Financial outlets like Seeking Alpha noted that while the drug successfully increased bone density, the failure to hit the primary endpoint of fracture reduction rendered the Phase 3 trials a clinical "dead end" for regulatory approval in the near term.

Analysts at major firms, as reported by MarketWatch, slashed price targets by over 80% following the December 2025 disclosure. The consensus shifted from viewing Mereo as a "growth play" to a "distressed asset," with commentators highlighting the massive cash burn associated with failed Phase 3 programs.

SEC Filings & Risk Factors

Plaintiffs allege that MREO’s public disclosures did not adequately convey the limitations of earlier clinical data. They further allege that the company failed to explain the uncertainty surrounding whether the Phase 2 findings would translate into reductions in fracture rates in the Phase 3 trials.

According to the complaint, the company’s statements did not fully convey the limitations of relying on bone mineral density improvements as evidence of reduced fracture risk. Plaintiffs allege that these omissions rendered the company’s public statements misleading.

Conclusion: Implications for Investors

The Mereo case underscores a recurring tension in biotech investing: the gap between encouraging early-stage signals and definitive late-stage clinical proof. Plaintiffs argue that the company blurred that distinction, presenting optimism as near-certainty.

For investors, the shift from promising surrogate indicators to disappointing clinical endpoints can be dramatic. The market reaction to the trial disclosures, including a sharp decline following the interim analysis and an even larger drop after the final results, illustrates how heavily biotech valuations often depend on the success of a single pivotal program.

For the broader market, the episode underscores a recurring reality in drug development: promising early signals can fuel investor optimism, but final clinical endpoints and the way companies communicate the risks leading up to them often determine how that optimism holds up once the data is fully revealed.

The lawsuit now asks whether Mereo’s public statements during the class period accurately reflected the limits of the earlier data and the uncertainty surrounding the Phase 3 trials. As the litigation proceeds, the case will likely turn on whether the company’s disclosures appropriately framed the relationship between improvements in bone density and the ultimate clinical goal of reducing fractures.

How to Join the Mereo BioPharma Group plc (MREO) Class Action:

• Confirm you purchased MREO ADS during the relevant class period
• Review eligibility details related to the federal securities claims
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.